<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12513112</PMID>
<DateCompleted>
<Year>2003</Year>
<Month>06</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1170-229X</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>20</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2003</Year>
</PubDate>
</JournalIssue>
<Title>Drugs &amp; aging</Title>
<ISOAbbreviation>Drugs Aging</ISOAbbreviation>
</Journal>
<ArticleTitle>Colorectal cancer in the elderly: is palliative chemotherapy of value?</ArticleTitle>
<Pagination>
<MedlinePgn>1-11</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Colorectal cancer is a disease of the elderly, with 70% of patients being aged 65 years or older. In Western countries, the total number of elderly patients with this disease is expected to further increase in the future. Since the incidence of adverse physical or socioeconomic conditions in the elderly is higher than in younger patients, a thorough assessment of the patient's suitability for therapy should be performed before a decision is made. Using a Comprehensive Geriatric Assessment (CGA) to subdivide the population of elderly cancer patients into three groups can help to guide treatment decisions. Both in the adjuvant and in the palliative setting, there are sufficient data supporting the use of fluorouracil-based chemotherapy in fit elderly patients who can tolerate cytotoxic treatment. Systemic chemotherapy has been shown to effectively reduce mortality in the adjuvant situation and to be of clinical benefit for patients with metastatic disease in terms of longer survival, control of symptoms and quality of life. In recent years, new substances such as oxaliplatin or irinotecan have shown significant activity in the treatment of patients with metastatic colorectal cancer. However, information on how to guide the use of these new drugs in elderly patients is still lacking. Limited data from clinical trials indicate treatment efficacy in selected elderly patients comparable to that observed in younger patients, with overall manageable toxicity. Clearly, further clinical trials in elderly patients with colorectal cancer are necessary as well as the incorporation of aspects of geriatric medicine into the teaching programme of medical oncologists.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Honecker</LastName>
<ForeName>Friedemann</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Department of Hematology/Oncology/Immunology, University Medical Center II, Eberhard-Karls-Universität, Tübingen, Federal Republic of Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Köhne</LastName>
<ForeName>Claus-Henning</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bokemeyer</LastName>
<ForeName>Carsten</ForeName>
<Initials>C</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>New Zealand</Country>
<MedlineTA>Drugs Aging</MedlineTA>
<NlmUniqueID>9102074</NlmUniqueID>
<ISSNLinking>1170-229X</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015179">Colorectal Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015577">Geriatric Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015201">Meta-Analysis as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D010166">Palliative Care</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>70</NumberOfReferences>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2003</Year>
<Month>1</Month>
<Day>7</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2003</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2003</Year>
<Month>1</Month>
<Day>7</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">12513112</ArticleId>
<ArticleId IdType="pii">200101</ArticleId>
<ArticleId IdType="doi">10.2165/00002512-200320010-00001</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Eur J Cancer. 2002 Feb;38(3):349-58</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11818199</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hematol Oncol Clin North Am. 2000 Feb;14(1):193-212, x-xi</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10680078</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 1995 Jan 1;75(1):11-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7804963</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2001 Nov 1;19(21):4097-106</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11689577</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2002 May 4;359(9317):1555-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12047964</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2000 Jan;18(1):136-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10623704</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ. 2000 Sep 2;321(7260):531-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10968812</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1997 Jan;15(1):110-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8996131</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1998 Sep;16(9):2943-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9738562</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2002 Feb;13(2):308-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11886010</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 1994 Oct;5(8):760-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7826910</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):13-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12199627</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Treat Rev. 2001 Aug;27(4):211-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11545541</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 1998 Nov;34(12):1871-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10023308</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2002 Mar 15;20(6):1491-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11896096</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2002 May;38(7):1000-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11978525</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2000 Apr;6(4):1205-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10778943</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Invest New Drugs. 2001;19(1):61-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11291833</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):35-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10442357</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1999 Aug;17(8):2412-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10561304</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2000 Mar;36(4):453-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10717521</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncology. 2001;61 Suppl 2:14-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11694783</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 1995 Mar;6(3):267-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7542021</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2001 Oct 11;345(15):1091-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11596588</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Rev Oncol Hematol. 2000 Jan;33(1):45-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10714961</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Rev Oncol Hematol. 2000 Feb;33(2):143-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10737376</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2001 Apr 15;19(8):2282-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11304782</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 1997 May 15;79(10):1884-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9149013</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 1998 Oct 31;352(9138):1413-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9807987</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Onkologie. 2001 Feb;24(1):87-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11441288</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 1996 Nov;7(9):961-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9006748</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 1990 Apr 28;335(8696):1020-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1970072</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 1999 Dec 30;341(27):2061-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10615079</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncologist. 2000;5(3):224-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10884501</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10200776</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2002 Apr;13(4):566-75</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12056707</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Clin Oncol. 1996 Aug;19(4):371-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8677907</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2002 Mar;38(4):478-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11872339</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 1999 Feb;79(3-4):627-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10027340</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 1995 Nov 2;333(18):1232-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7565998</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2001 Jul 12;345(2):144-5; author reply 146</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11450666</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2000 May 15;88(10):2398-424</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10820364</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2000 Sep;36(14):1741-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10974621</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2001 Nov 1;345(18):1351-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11794165</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2001 Apr;12(4):435-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11398873</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1992 Jun;10(6):904-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1588370</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Oncol. 1999 Feb;26(1 Suppl 5):13-20</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10213010</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Oncol. 2002 Oct;29(5 Suppl 14):10-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12422309</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2000 Mar 25;355(9209):1041-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10744089</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncology. 2001;61(1):36-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11474246</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Chemother Pharmacol. 1998;42(4):336-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9744780</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2002 Jan 24;346(4):235-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11807147</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Acta Oncol. 1992;31(6):645-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1281650</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ. 1993 Mar 20;306(6880):752-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7683942</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2000 Aug;18(16):2938-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10944126</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 1997 Feb;33(2):214-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9135491</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Saf. 2000 Oct;23(4):255-78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11051215</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 1996 Sep;7(7):657-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8905021</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drugs Aging. 2001;18(12):935-48; discussion 949-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11888348</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 1998 Aug;16(8):2739-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9704726</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 1999 Feb 15;85(4):786-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10091755</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>